Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24218745 | 0.84 | LOXL2 (0.41) | CNR2CNR1LOXL2GPR3PTPN1 | |
| SCHEMBL12922043 | 0.75 | GPR3 (0.46) | LOXL2GPR3L3MBTL1KDM4ERAB9A | |
| SCHEMBL811436 | 0.75 | GPR3 (0.46) | LOXL2GPR3KDM4ERAB9AMEN1 | |
| SCHEMBL2388976 | 0.75 | CNR2 (0.46) | CNR2CNR1LOXL2GPR3PTPN1 | |
| SCHEMBL14045624 | 0.75 | CNR2 (0.46) | CNR2CNR1LOXL2GPR3PTPN1 | |
| SCHEMBL31190192 | 0.75 | GPR3 (0.46) | LOXL2GPR3KDM4ERAB9AMEN1 | |
| SCHEMBL13352406 | 0.73 | CNR2 (0.45) | CNR2CNR1LOXL2GPR3PTPN1 | |
| SCHEMBL31078701 | 0.73 | CNR2 (0.49) | CNR2CNR1LOXL2GPR3PTPN1 | |
| SCHEMBL22810223 | 0.73 | CNR2 (0.45) | CNR2CNR1LOXL2GPR3PTPN1 | |
| SCHEMBL31412193 | 0.73 | GPR3 (0.44) | LOXL2GPR3KDM4ERAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10702861-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200030783-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CNR2 1055/4885CNR1 1123/4885LOXL2 1643/4885 |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CNR2 1055/4885CNR1 1123/4885LOXL2 1643/4885 |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | CNR2 11/4885CNR1 6/4885LOXL2 3006/4885 |
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | CNR2 24/4885CNR1 45/4885LOXL2 3996/4885 |
| US-20200030783-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | CNR2 570/4885CNR1 379/4885LOXL2 822/4885 |
| US-10702861-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | CNR2 570/4885CNR1 379/4885LOXL2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.